Posts Tagged ‘Biotech’
Hedera Dx Secures €15 Million Series A
Hedera Dx Raises €15M Series A to Expand Access to Precision Oncology Across Europe Hedera Dx, a Vaud-Based techbio company advancing precision cancer care, announced the successful close of a €15 million Series A financing round. The round was led by Vsquared Ventures, with new investor Tesi joining and strong support from existing backers…
Read MoreTimeline® Named Milestone 1 Award Winner in XPRIZE Healthspan Competition
Timeline®, a leading longevity biotech company (parent company Amazentis in Canton of Vaud) and maker of Mitopure®, has been named a Milestone 1 Award Winner in the prestigious XPRIZE Healthspan competition. Selected from hundreds of global entrants, Timeline is among the Top 40 international teams recognized for advancing innovative, safe, and science-backed solutions to extend…
Read MoreRepronovo raises $65 million in series A
ReproNovo, a Vaud-Based company dedicated to developing innovative treatments for reproductive medicine and women’s health, announced the successful closing of a $65 million Series A financing round. The round was led by Jeito Capital, co-led by AXA IM Alts and founding investor M Ventures, with strong syndicate support from Ysios Capital and ALSA Ventures. The…
Read MoreSwiss Biotech Sector Shows Strength and Growth in 2024
Despite a challenging global market environment, the Swiss biotech sector once again demonstrated strength and resilience in 2024, as detailed in the newly released 2025 Swiss Biotech Report presented on 5 May 2025 during the Swiss Biotech Days. Co-authored by the Swiss Biotech Association, EY, and eight partner organizations, the report offers a deep dive…
Read MoreArtiria Medical and Reverso Therapeutics Awarded at BIND – BioInnovation Day
250 key players of the Swiss Health Valley gathered at Campus Biotech Geneva on 1 April 2025 for the 10th edition of BIND-BioInnovation Day. 29 groundbreaking life sciences projects developed in Western Switzerland Academic Institutions pitched in front of the audience. Artiria Medical and Reverso Therapeutics won the Best Startup Award and the Best Academic…
Read MoreSiegfried opens new global R&D Center for Drug Substances in Evionnaz
Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen (Switzerland), inaugurated its new global Research and Development (R&D) Center for Drug Substances at its site in Evionnaz, Switzerland. The 4,500m2 R&D Center houses advanced chemical and analytical facilities, state-of-the-art laboratories, and cutting-edge technologies such…
Read MoreTakeda Neuchâtel receives the BioAlps Industry Award 2024
The BioAlps Awards 2024 ceremony took place on 21 November 2024 at the University of Fribourg in front of around 250 key players from the Swiss Health Valley, at the end of the BioAlps Networking Day. The Neuchâtel site of the Japanese biotech company Takeda received the BioAlps Industry Prize 2024. Takeda Neuchâtel produces…
Read MoreBracco invests EUR 80 Million in Geneva
Over 80 million euros have been invested to build Hexagon, a new multi-functional building located next to the historical 1997 plant in Plan-les-Ouates (Geneva – Switzerland). On 6 November 2024, Bracco inaugurated a new 4-story building characterized by contemporary design and constructed according to the most rigorous sustainability standards in Geneva, which will,…
Read MoreLonza to Expand Bioconjugation in Visp with Two Additional Manufacturing Suites
Fantastic news for the Swiss Health Valley! After announcing the creation of 100 new jobs in October, Lonza announces the increase of its bioconjugation capabilities with two additional manufacturing sites in Visp (Valais). 200 other new jobs will be created. Lonza, a global development and manufacturing partner to the pharmaceutical, biotech and nutraceutical…
Read MoreDuhn Therapeutics signs global license agreement with OM Pharma
Duhn Therapeutics SAS, a clinical-stage company co-founded by Landmark BioVentures AG, and OM Pharma SA, a global biopharmaceutical company and leader in bacterial lysate products, announce an exclusive licence agreement to advance the development and commercialization of lead candidate DHN198, previously OM-174, in a pipeline of lipid-based cancer immunotherapies. Duhn Therapeutics, with executive…
Read More